Determination of serum vitamin D3 levels in patients with acute lymphoblastic leukemia
Archives of Medical Laboratory Sciences,
Vol. 4 No. 4 (2018),
16 February 2020
https://doi.org/10.22037/amls.v4i4.27894
Abstract
Background: Regarding the role of vitamin D3 as a steroid hormone in regulating the metabolism of minerals and bone homeostasis, its antitumor role has been confirmed in epidemiologic and empirical studies. Accordingly, this investigation conducted on acute lymphoblastic leukemia (ALL) patients to understand whether vitamin D3 has role in increasing the risk of getting ALL or not.Materials and Methods:In this study, 40 patients with acute lymphoblastic leukemia were included after confirmation of cytological tests in Hamedan, Qazvin and Tehran. Moreover, 40 healthy persons without any hematologic diseases in both themselves and their immediate relatives were selected. The level of vitamin D3 in blood serum of patients and control group was measured with Chemiluminscence method.Results:Ninety percent of the subjects in the experimental group and 75% of the control group suffered from severe vitamin D3 deficiency. 10% of the experimental group and 20% of the control group had a mild to moderate vitamin D3 deficiency and range from 10 - 19 ng / ml. Among ALL patients, none of them had the desired level (20- 50 ng / ml) of vitamin D3, while two persons in the control group had a desirable level of vitamin D3 with a range of 20- 50 ng / ml. It is found that there is a significant difference between mean of vitamin D3 level in acute lymphoblastic leukemia patients and healthy control group (p <0.05).Conclusion:It seems that there is a correlation between the incidence of ALL and serum vitamin D3 level. However, additional studies are needed to understand more about the mechanisms of this.
- Vitamin D3
- Acute lymphoblastic leukemia
- Vitamin D3 deficiency
- Cytological tests
How to Cite
References
Dastgiri S, Fozounkhah S, Shokrgozar S, Taghavinia M, Kerman AA. Incidence of Leukemia in the Northwest of Iran. Health Promotion Perspectives. 2011;Vol. 1( No. 1):50-3.
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. The lancet oncology. 2009;10(2):147-56.
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013;381(9881):1943-55.
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England journal of medicine. 2014;371(11):1005-15.
Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. Environmental health perspectives. 2006;115(1):138-45.
Bhojwani D, Kang H, Moskowitz NP, Min D-J, Lee H, Potter JW, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006;108(2):711-7.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59(4):225-49.
Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, et al. 1α, 25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochemical and biophysical research communications. 1981;102(3):937-43.
Wei MY, Giovannucci EL. Vitamin D and multiple health outcomes in the Harvard cohorts. Molecular nutrition & food research. 2010;54(8):1114-26.
Trump DL, Deeb K, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer journal (Sudbury, Mass). 2010;16(1):1.
Ozono K, Saito M, Miura D, Michigami T, Nakajima S, Ishizuka S. Analysis of the molecular mechanism for the antagonistic action of a novel 1α, 25-dihydroxyvitamin D3 analogue toward vitamin D receptor function. Journal of Biological Chemistry. 1999;274(45):32376-81.
Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? Progress in biophysics and molecular biology. 2006;92(1):132-9.
A Victor Hoffbrand DC, Edward GD Tuddenham and Anthony R Green. Postgraduate Haematology2010.
Wang X, Studzinski GP. Activation of extracellular signal‐regulated kinases (ERKs) defines the first phase of 1, 25‐dihydroxyvitamin D3‐induced differentiation of HL60 cells. Journal of cellular biochemistry. 2001;80(4):471-82.
Garland C, Garland F, Shaw E, Comstock G, Helsing K, Gorham E. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. The Lancet. 1989;334(8673):1176-8.
Thomas X, Chelghoum Y, Fanari N, Cannas G. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. Hematology. 2011;16(5):278-83.
Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117(5):1492-8.
Naz A, Qureshi RN, Shamsi TS, Mahboob T. Vitamin D levels in patients of acute leukemia before and after remission-induction therapy. Pakistan journal of medical sciences. 2013;29(1):10.
Pistor MS, L Haupeltshofer, S, Miclea A, Faissner S, Chan A, Hoepner R. 1,25-OH2 vitamin D3 and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL). Leuk Research Reports. 2018;17(9):38-41.
Delvin EA, N Rauch, F, Marci lV, More lS, Boisvert M, Lecours M, Laverdière C, et al. Vitamin D nutritional status and bone turnover markers in childhood acute lymphoblastic leukemia survivors: A PETALE study. Clinical Nutrition. 2019;38(2):912-9.
- Abstract Viewed: 129 times
- PDF Downloaded: 103 times